Wealth Enhancement Advisory Services LLC Has $42.47 Million Stock Position in Danaher Corporation (NYSE:DHR)

Wealth Enhancement Advisory Services LLC boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 4.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 207,169 shares of the conglomerate's stock after buying an additional 7,907 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Danaher were worth $42,470,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FAS Wealth Partners Inc. grew its position in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Danaher by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock valued at $933,524,000 after buying an additional 135,047 shares in the last quarter. Camden National Bank grew its holdings in Danaher by 285.0% in the 4th quarter. Camden National Bank now owns 7,227 shares of the conglomerate's stock valued at $1,659,000 after buying an additional 5,350 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after acquiring an additional 579,046 shares in the last quarter. Finally, Terra Alpha Investments LLC acquired a new position in shares of Danaher in the fourth quarter valued at about $3,068,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Shares of Danaher stock opened at $196.23 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The firm has a market capitalization of $140.43 billion, a P/E ratio of 38.10, a P/E/G ratio of 2.73 and a beta of 0.77. The company's 50 day moving average price is $193.89 and its two-hundred day moving average price is $209.69.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. On average, equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher's dividend payout ratio is presently 24.85%.

Analyst Upgrades and Downgrades

DHR has been the topic of several research reports. Wall Street Zen downgraded shares of Danaher from a "buy" rating to a "hold" rating in a research note on Monday, June 9th. TD Cowen increased their target price on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. UBS Group reduced their price target on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. HSBC reduced their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Finally, Wolfe Research reduced their price target on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research report on Monday, April 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $248.17.

Insider Buying and Selling

In other news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.